Evidence map›Paper›PMID 36195888›Full record

ArticleOrphanet journal of rare diseases2022

Understanding caregiver descriptions of initial signs and symptoms to improve diagnosis of metachromatic leukodystrophy.

F Eichler, Caroline Sevin, M Barth, F Pang, K Howie, M Walz, A Wilds, C Calcagni, C Chanson, L Campbell

Open access · goldAbstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Rigorous genetic diagnosis review in natural history studies.Orphanet journal of rare diseases · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. AnMolecular genetics and metabolism reports · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

F EichlerCenter for Rare Neurological Diseases, Massachusetts General Hospital, Boston, MA, USA.
Caroline SevinService de Neuropédiatrie, centre de reference des leucodystrophies et leucoencephalopathies genetiques de cause rare, CHU Paris-Sud-Hôpital de Bicêtre, Le Kremlin-Bicêtre, France.
M BarthService de Génétique, Hôpital Universitaire d'Angers, Angers, France.
F PangOrchard Therapeutics, 245 Hammersmith Road, London, W6 8PW, UK. francis.pang@orchard-tx.com.ORCID 0000-0002-9572-8779
K HowieMagnolia Innovation, Hoboken, NJ, USA.
M WalzMagnolia Innovation, Hoboken, NJ, USA.
A WildsMagnolia Innovation, Hoboken, NJ, USA.
C CalcagniMagnolia Innovation, Hoboken, NJ, USA.
C ChansonOrchard Therapeutics, 245 Hammersmith Road, London, W6 8PW, UK.
L CampbellOrchard Therapeutics, 245 Hammersmith Road, London, W6 8PW, UK.
Centre Hospitalier Universitaire d'Angers · FRHarvard University · USThe Francis Crick Institute · GB

Funding

Validation of the GMFC-MLDU54NS115052 · NINDS · CHILDREN'S HOSP OF PHILADELPHIA · PI Laura Ann Adang, FLORIAN S EICHLER · 2019 to 2026
$14.3M
NINDS NIH HHS U54 NS115052
6 · The paper itself

Abstract

backgroundMetachromatic leukodystrophy (MLD), a relentlessly progressive and ultimately fatal condition, is a rare autosomal recessive lysosomal storage disorder caused by a deficiency of the enzyme arylsulfatase A (ARSA). Historically management has been palliative or supportive care. Hematopoietic stem cell transplantation is poorly effective in early-onset MLD and benefit in late-onset MLD remains controversial. Hematopoietic stem cell gene therapy, Libmeldy (atidarsagene autotemcel), was recently approved by the European Medicines Agency for early-onset MLD. Treatment benefit is mainly observed at an early disease stage, indicating the need for early diagnosis and intervention. This study contributes insights into the caregiver language used to describe initial MLD symptomatology, and thereby aims to improve communication between clinicians and families impacted by this condition and promote a faster path to diagnosis.

resultsData was collected through a moderator-assisted online 60-min survey and 30-min semi-structured follow-up telephone interview with 31 MLD caregivers in the United States (n = 10), France (n = 10), the United Kingdom (n = 5), and Germany (n = 6). All respondents were primary caregivers of a person with late infantile (n = 20), juvenile (n = 11) or borderline late infantile/juvenile (n = 1) MLD (one caregiver reported for 2 children leading to a sample of 32 individuals with MLD). Caregivers were asked questions related to their child's initial signs and symptoms, time to diagnosis and interactions with healthcare providers. These results highlight the caregiver language used to describe the most common initial symptoms of MLD and provide added context to help elevate the index of suspicion of disease. Distinctions between caregiver descriptions of late infantile and juvenile MLD in symptom onset and disease course were also identified.

conclusionsThis study captures the caregiver description of the physical, behavioral, and cognitive signs of MLD prior to diagnosis. The understanding of the caregiver language at symptom onset sheds light on a critical window of often missed opportunity for earlier diagnosis and therapeutic intervention in MLD.

Indexed as

Leukodystrophy, MetachromaticLysosomal Storage DiseasesCaregiversCerebroside-SulfataseChildDisease ProgressionHumansCerebroside-SulfataseCaregiver experienceCaregiver languageDiagnostic delayDisease onsetEarly-onsetInitial symptomsJuvenileLate infantileMetachromatic leukodystrophyMLD

Identifiers

PMID36195888
PMCPMC9531467
OpenAlexW4301397386

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.